Application of a new highly multiplexed amplicon sequencing tool to evaluate antimalarial resistance and relatedness in individual and pooled samples from Dschang, Cameroon.

Background: Resistance to antimalarial drugs remains a major obstacle to malaria elimination. Multiplexed, targeted amplicon sequencing is being adopted for surveilling resistance and dissecting the genetics of complex malaria infections. Moreover, genotyping of parasites and detection of molecular markers drug resistance in resource-limited regions requires open-source protocols for processing samples, using accessible reagents, and rapid methods for processing numerous samples including pooled sequencing.

Intermediate-Dose Post-Transplantation Cyclophosphamide for Myeloablative HLA-Haploidentical Bone Marrow Transplantation.

High-dose post-transplantation cyclophosphamide (HD-PTCy), given at 50 mg/kg/day on days +3/+4, is a standard-of-care graft-versus-host disease (GVHD) prophylaxis for allogeneic hematopoietic cell transplantation (HCT). Our murine MHC-haploidentical HCT studies suggested intermediate-dose PTCy produces superior GVHD control compared with HD-PTCy and PTCy is maximally effective on day +4. We conducted a single-institutional prospective phase I/II trial (NCT03983850) to reduce PTCy dosing to 25 mg/kg/day on days +3/+4 or on day +4 only for myeloablative HLA-haploidentical bone marrow HCT using PTCy, sirolimus, and mycophenolate mofetil.

Diversity, abundance of anopheline species, and malaria transmission dynamics in high-altitude areas of western Cameroon.

Background: Assessing vector bionomics is crucial to improving vector control strategies. Several entomological studies have been conducted to describe malaria transmission in different eco-epidemiological settings in Cameroon; knowledge gaps persist, particularly in highland areas. This study aimed to characterize malaria vectors in three localities along an altitudinal gradient in the western region: Santchou (700 m), Dschang (1400 m), and Penka Michel (1500 m).

Emergence and Rising Prevalence of Artemisinin Partial Resistance Marker Kelch13 P441L in a Low Malaria Transmission Setting in Southern Zambia.

Increasing artemisinin partial resistance (ArtR) due to mutations in the gene encoding Kelch13 () protein in eastern Africa is of urgent concern, and mutations, such as P441L, continue to emerge. We used an amplicon deep-sequencing panel to estimate the prevalence of ArtR mutations in samples collected between 2018 and 2023 in southern Zambia. P441L was present in 30 of 501 samples (6%), and prevalence increased over time (0% to 7.